Open-label, multicenter, randomized, comparative study in parallel groups

Group I will be administered Dalteparin Sodium, solution for intravenous and subcutaneous administration 5 000 anti-Xa IU/0.2 ml ("Camus Pharma Pvt. Ltd.", India) subcutaneously in a dose of 5000 IU in the evening before the day of surgery, then 5000 IU every evening after the surgery. Therapy will last for 12-14 days (including the day of surgery) depending on regular procedure of the clinical site.

Group II will be administered Fragmin®, solution for intravenous and subcutaneous administration 5000 anti-Xa IU/0.2 ml ("Pfizer MFG. Belgium N.V.", Belgium) subcutaneously in a dose of 5000 IU in the evening before the surgery, then 5000 IU every evening after the surgery. Therapy will last for 12-14 days (including the day of surgery), depending on regular procedure of the clinical site.

Intermediate visit to evaluate tolerability and safety of study therapy will be performed after 5 days ± 2 days.

Evaluation of therapy efficacy and safety will be performed after 14 ± 2 days of therapy, then depending on Investigator‘s conclusion, a patient will be discharged from the hospital and will be administered oral forms of anticoagulants as per the standard practice of clinical site (oral forms of anticoagulants approved in the RF: warfarin, dabigatran, rivaroxaban). If patient‘s condition is not acceptable for outpatient treatment, his hospitalization may be prolonged.

Test drug and reference drug are administered subcutaneously, injection sites should be changed daily (contralateral injections every next day of treatment).